The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes

被引:84
作者
Lind, M. [1 ,2 ]
Olsson, M. [3 ]
Rosengren, A. [2 ]
Svensson, A-M [4 ]
Bounias, I. [1 ]
Gudbjornsdottir, S. [5 ]
机构
[1] Uddevalla Cent Hosp, Dept Med, S-45180 Uddevalla, Sweden
[2] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Gothenburg, Sweden
[3] Chalmers Univ Technol, Dept Math Sci, S-41296 Gothenburg, Sweden
[4] Ctr Registers Reg Vastra Gotaland, Gothenburg, Sweden
[5] Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Med, Gothenburg, Sweden
基金
瑞典研究理事会;
关键词
Glycaemic control; HbA(1c); Heart failure; Incidence; Riskestimation; Type; 1; diabetes; 2; POSITION STATEMENT; ASSOCIATION; GLUCOSE; RISK; COMPLICATIONS; PREVENTION; MANAGEMENT; MORTALITY; SURVIVAL; MELLITUS;
D O I
10.1007/s00125-012-2681-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to examine the relationship between glycaemic control and hospitalisation for heart failure in patients with type 2 diabetes. Patients included in the Swedish National Diabetes Register (NDR) during 1998-2003 were followed until hospitalisation for heart failure, death or 31 December 2009. Unadjusted and adjusted incidence rates for heart failure were estimated by Poisson regression and relative risk was estimated by Cox regression. In 83,021 patients with type 2 diabetes, 10,969 (13.2%) were hospitalised with a primary or secondary diagnosis of heart failure during a mean follow-up of 7.2 years. The incidence increased by male sex (p < 0.001), older age (p < 0.001) and longer diabetes duration (p < 0.001). In Cox regression adjusting for risk factors of heart failure the HR per each percentage unit higher HbA(1c) (10 mmol/mol) for heart-failure hospitalisation was 1.12 (95% CI 1.10, 1.14). By category of HbA(1c) the HR for heart failure hospitalisation was: HbA(1c) 6.0 to < 7.0% (42 to < 53 mmol/mol), 0.91 (95% CI 0.84, 0.98); HbA(1c) 7.0 to < 8.0% (53 to < 64 mmol/mol), 0.99 (95% CI 0.91, 1.07); HbA(1c) 8.0 to < 9.0% (64 to < 75 mmol/mol), 1.10 (95% CI 1.01, 1.20); HbA(1c) 9.0 to < 10.0% (75 to < 86 mmol/mol), 1.27 (95% CI 1.15, 1.41); HbA(1c) a parts per thousand yen10.0 % (a parts per thousand yen86 mmol/mol), 1.71 (1.51, 1.93) (reference HbA(1c) < 6% [42 mmol/mol]). The HR for patients with HbA(1c) 7.0 to < 8.0% (53 to < 64 mmol/mol) compared with patients with HbA(1c) 6.0 to < 7.0% (42 to < 53 mmol/mol) was 1.09 (95% CI 1.03, 1.14). Poor glycaemic control (HbA(1c) > 7% [53 mmol/mol]) is associated with an increased risk of hospitalisation for heart failure in patients with type 2 diabetes.
引用
收藏
页码:2946 / 2953
页数:8
相关论文
共 26 条
[1]   Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes [J].
Aguilar, David ;
Bozkurt, Biykem ;
Ramasubbu, Kumudha ;
Deswal, Anita .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (05) :422-428
[2]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[3]   Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study [J].
Currie, Craig J. ;
Peters, John R. ;
Tynan, Aodan ;
Evans, Marc ;
Heine, Robert J. ;
Bracco, Oswaldo L. ;
Zagar, Tony ;
Poole, Chris D. .
LANCET, 2010, 375 (9713) :481-489
[4]   New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR) [J].
Eeg-Olofsson, K. ;
Cederholm, J. ;
Nilsson, P. M. ;
Zethelius, B. ;
Svensson, A. -M. ;
Gudbjornsdottir, S. ;
Eliasson, B. .
JOURNAL OF INTERNAL MEDICINE, 2010, 268 (05) :471-482
[5]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
[6]   IFCC reference system for measurement of hemoglobin Alc in human blood and the National Standardization Schemes in the United States, Japan, and Sweden:: A method-comparison study [J].
Hoelzel, W ;
Weykamp, C ;
Jeppsson, JO ;
Miedema, K ;
Barr, JR ;
Goodall, I ;
Hoshino, T ;
John, WG ;
Kobold, U ;
Little, R ;
Mosca, A ;
Mauri, P ;
Paroni, R ;
Susanto, F ;
Takei, I ;
Thienpont, L ;
Umemoto, M ;
Wiedmeyer, HM .
CLINICAL CHEMISTRY, 2004, 50 (01) :166-174
[7]   10-year follow-up of intensive glucose control in type 2 diabetes [J].
Holman, Rury R. ;
Paul, Sanjoy K. ;
Bethel, M. Angelyn ;
Matthews, David R. ;
Neil, H. Andrew W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589
[8]   The validity of a diagnosis of heart failure in a hospital discharge register [J].
Ingelsson, E ;
Ärnlöv, J ;
Sundström, J ;
Lind, L .
EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (05) :787-791
[9]   Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J].
Inzucchi, S. E. ;
Bergenstal, R. M. ;
Buse, J. B. ;
Diamant, M. ;
Ferrannini, E. ;
Nauck, M. ;
Peters, A. L. ;
Tsapas, A. ;
Wender, R. ;
Matthews, D. R. .
DIABETOLOGIA, 2012, 55 (06) :1577-1596
[10]  
Iribarren C, 2001, CIRCULATION, V103, P2668